ReviewCNS drugs2016
A Review of Treatment Options for Progressive Supranuclear Palsy.
Review in CNS drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Available and future treatments for atypical parkinsonism. A systematic review.CNS neuroscience & therapeutics · 2019Pooled it
- Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.Parkinsonism & related disorders · 2019Trial
- Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.Movement disorders : official journal of the Movement Disorder Society · 2017Trial
- Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory.Movement disorders : official journal of the Movement Disorder Society · 2024Article
- Efficiency of multivariate tests in trials in progressive supranuclear palsy.Scientific reports · 2024Article
- Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.Nature reviews. Neurology · 2021Review
- Understanding fatigue in progressive supranuclear palsy.Scientific reports · 2021Article
- Therapeutic Application of rTMS in Atypical Parkinsonian Disorders.Behavioural neurology · 2021Review
- Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.Frontiers in neurology · 2021Review
- Alteration of the Dopamine Receptors' Expression in the Cerebellum of the Lysosomal Acid Phosphatase 2 Mutant (Naked-Ataxia (International journal of molecular sciences · 2020Article
- Associations Between Amantadine Usage, Gait, and Cognition in PSP: AFrontiers in neurology · 2020Article
- The Role of Tau Imaging in Parkinsonian Disorders.Current neurology and neuroscience reports · 2018Review
- Review
- Neurotransmitter deficits from frontotemporal lobar degeneration.Brain : a journal of neurology · 2018Review
- Progressive Supranuclear Palsy: an Update.Current neurology and neuroscience reports · 2018Review
- A randomized, single ascending dose study of intravenous BIIB092 in healthy participants.Alzheimer's & dementia (New York, N. Y.) · 2018Article
- Tau Diagnostics and Clinical Studies.Journal of molecular neuroscience : MN · 2017Article
- Differentiation of atypical Parkinson syndromes.Journal of neural transmission (Vienna, Austria : 1996) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive supranuclear palsy (PSP) is an atypical parkinsonian condition characterized by a symmetric akinetic-rigid syndrome, early falls, supranuclear gaze palsy, and a frontotemporal behavioral syndrome. The typical phenotype is termed Richardson's syndrome, but numerous other phenotypes have been described. The pathophysiology of PSP is not fully understood, but dysfunction of the tau protein seems to play a central role. Despite exciting new knowledge on the pathophysiology of PSP, there is still no highly effective symptomatic or disease-modifying treatment. We review the evidence on pharmacotherapy and experimental therapies in PSP and provide levels of recommendation for the off-label use of commonly used drugs in this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.